HERAMED LIMITED — Capital/Financing Update 2020

May 31, 2020

Market Announcement

==> picture [33 x 50] intentionally omitted <==

1 June 2020

==> picture [451 x 5] intentionally omitted <==

HeraMED Limited (ASX: HMD) – Trading Halt (2+2)

Description

The securities of HeraMED Limited (‘HMD’) will be placed in trading halt at the request of HMD, pending it releasing an announcement regarding a capital raising. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 5 June 2020 or when the announcement is released to the market.

Issued by

Sandra Wutete

Senior Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

1 June 2020 ASX Limited

1 June 2020

==> picture [85 x 45] intentionally omitted <==

ASX ANNOUNCEMENT

Anjuli Sinniah Senior Adviser, Listings Compliance ASX Operations Level 40 Central Park 152-158 St George’s Terrace PERTH WA 6000

Via Email: tradinghaltsperth@asx.com.au

Dear Ms Sinniah

TRADING HALT REQUEST

Medical technology company, HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”) requests that the securities of the Company be placed in two consecutive trading halts of up to four trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

1. The two consecutive trading halts are requested for the purposes of considering, planning and executing a capital raising.

2. The Company requests that the consecutive trading halts remain in place until the earlier of the Company releasing an announcement regarding the capital raising or prior to the commencement of trading on Friday, 5 June 2020.

3. The Company is not aware of any reason why the request for the two consecutive trading halts should not be granted or any other information necessary to inform the market about the consecutive trading halts.

Your faithfully

Jonathan Hart

Company Secretary

-ENDS-

HeraMED Limited ACN 626 295 314 T: +61 2 8379 2961 | A: Suite 3, Level 10, 23-25 Hunter Street SYDNEY NSW 2000